A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Table 2

Clinical and pathological characteristics divided by DFS-INPS.

Variables
		Age (median (IQR))	49.00 (42.00-57.00)		49.00 (42.00-57.00)	47.50 (42.00-57.00)	0.904
Age
≤ 49	132 (53.0)	102 (52.8)	30 (53.6)	1
> 49	117 (47.0)	91 (47.2)	26 (46.4)
Position
Left	140 (56.2)	110 (57.0)	30 (53.6)	0.763
Right	109 (43.8)	83 (43.0)	26 (46.4)
Menopause
0	137 (55.0)	102 (52.8)	35 (62.5)	0.26
1	112 (45.0)	91 (47.2)	21 (37.5)
Parturition
0	31 (12.4)	21 (10.9)	10 (17.9)	0.219
1	156 (62.7)	126 (65.3)	30 (53.6)
≥ 2	62 (24.9)	46 (23.8)	16 (28.6)
Clinical T stage
1	22 (8.8)	17 (8.8)	5 (8.9)	0.026
2	175 (70.3)	142 (73.6)	33 (58.9)
3	48 (19.3)	33 (17.1)	15 (26.8)
4	4 (1.6)	1 (0.5)	3 (5.4)
Clinical N stage
0	8 (3.2)	6 (3.1)	2 (3.6)	0.715
1	28 (11.2)	23 (11.9)	5 (8.9)
2	153 (61.4)	115 (59.6)	38 (67.9)
3	60 (24.1)	49 (25.4)	11 (19.6)
Clinical TNM stage
II	32 (12.9)	27 (14.0)	5 (8.9)	0.442
III	217 (87.1)	166 (86.0)	51 (91.1)
Molecular subtype
Luminal A	39 (15.7)	34 (17.6)	5 (8.9)	0.165
Luminal B	117 (47.0)	86 (44.6)	31 (55.4)
HER-2 OE	50 (20.1)	42 (21.8)	8 (14.3)
TNBC	43 (17.3)	31 (16.1)	12 (21.4)
ER
Negative	98 (39.4)	77 (39.9)	21 (37.5)	0.867
Positive	151 (60.6)	116 (60.1)	35 (62.5)
PR
Negative	123 (49.4)	98 (50.8)	25 (44.6)	0.511
Positive	126 (50.6)	95 (49.2)	31 (55.4)
HER-2
Negative	99 (39.8)	83 (43.0)	16 (28.6)	0.045
Low expression	75 (30.1)	51 (26.4)	24 (42.9)
Positive	75 (30.1)	59 (30.6)	16 (28.6)
Ki-67
<20%	107 (43.0)	93 (48.2)	14 (25.0)	0.003
≥ 20%	142 (57.0)	100 (51.8)	42 (75.0)
P53
Negative	182 (73.1)	148 (76.7)	34 (60.7)	0.028
Positive	67 (26.9)	45 (23.3)	22 (39.3)
Cycle
≤ 4	148 (59.4)	117 (60.6)	31 (55.4)	0.581
>4	101 (40.6)	76 (39.4)	25 (44.6)
L (median (IQR))	1.92 (1.60-2.45)	2.13 (1.75-2.61)	1.53 (1.36-1.83)	<0.001
N (median (IQR))	3.78 (3.00-4.73)	3.42 (2.86-4.22)	5.03 (4.42-6.22)	<0.001
M (median (IQR))	0.41 (0.34-0.52)	0.38 (0.31-0.47)	0.50 (0.41-0.58)	<0.001
HB (median (IQR))	135.0(128.3-141.0)	135.0(129.2-140.0)	133.5(126.1-142.3)	0.532
P (median (IQR))	239.0 (210-283)	238.0(210-278)	256.5(211-299)	0.293
ALB (median (IQR))	45.00 (43.00-46.50)	45.00 (43.00-46.30)	45.00 (43.00-46.78)	0.895
GLOB (median (IQR))	30.00 (27.60-33.00)	30.00 (27.30-33.00)	30.00(28.0-33.12)	0.621
BMI (median (IQR))	24.00 (21.80-26.70)	24.0 (21.60-26.60)	23.9(22.08-27.55)	0.242
PNI (median (IQR))	55.10 (52.30-57.50)	55.50 (52.90-58.10)	52.55(50.6-55.12)	<0.001
AGR (median (IQR))	1.48 (1.35-1.64)	1.50 (1.38-1.64)	1.46(1.33-1.61)	0.444
NLR (median (IQR))	1.87 (1.45-2.47)	1.66 (1.37-2.03)	3.20(2.75-3.64)	<0.001
PLR (median (IQR))	120.00(98-150)	113 (95-136)	162(130-206)	<0.001
MLR (median (IQR))	0.20 (0.16-0.27)	0.19 (0.15-0.22)	0.32(0.27-0.37)	<0.001
SII (median (IQR))	441 (329-630)	397 (299-509)	813(682-1001)	<0.001
SIRI (median (IQR))	0.77 (0.51-1.14)	0.64 (0.48-0.86)	1.52(1.36-2.08)	<0.001

Abbreviations: INPS, inflammation and nutrition prognostic score; IQR, interquartile range; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; HER-2 OE, HER-2 overexpression; L, lymphocyte; N, neutrophil; M, monocyte; Hb, hemoglobin; P, platelet; ALB, albumin; GLOB, globulin; BMI, body mass index; PNI, prognostic nutritional index; AGR, albumin-globulin ratio; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; MLR, monocyte-lymphocyte ratio; SII, systemic immune inflammation index; SIRI, systemic inflammation response index.